[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100113832":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":25,"locations":25,"responsibleParty":33,"collaborators":25,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":25,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":25,"enrollmentInfo":44,"targetDuration":25,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":25,"overallStatus":53,"whyStopped":54,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":25},{"fullName":5,"class":6},"Nycomed","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"1","ACTIVE_COMPARATOR","NYC 0462 Ointment",[13],"Drug: NYC 0462 Ointment",{"label":15,"type":16,"description":17,"interventionNames":18},"2","PLACEBO_COMPARATOR","Placebo",[19],"Drug: Placebo",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis",[9],null,{"type":22,"name":17,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":31,"role":32},"Kathleen Ocasio","Fougera Pharmaceuticals Inc.","STUDY_CHAIR",{"type":25,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":30,"oldOrganization":34},"Nycomed US Inc.","100113832","phase-3-to-demonstrate-the-superior-efficacy-of-nyc-0462-ointment-over-that-of-the-placebo-in-the-treatment-of-plaque-psoriasis-100113832",false,"NCT00747032","To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis","Multi-Center, Double-Blind, Randomized, Vehicle-controlled, Parallel-Group Study Comparing NYC-0462 Ointment To a Vehicle Control","Inclusion Criteria:\n\n* Diagnosis of stable, symptomatic plaque psoriasis\n* Good health with the exception of psoriasis\n* % BSA and plaque elevation requirements\n\nExclusion Criteria:\n\n* Subjects who are pregnant, nursing or planning a pregnancy within the study participation period.\n* Subjects who have any systemic or dermatological disorders with the exception of psoriasis","ALL","18 Years",{"count":45,"type":46},0,"ACTUAL","INTERVENTIONAL",[49],"PHASE3","The aim of this trial is to assess the efficacy of NYC-0462 Ointment in the Treatment of Plaque Psoriasis.Treatment medication will be administered as follows: A thin layer of study product will be applied to the affected skin, excluding the face, once daily, at approximately the same time daily.",[52],"Plaque Psoriasis","WITHDRAWN","Study withdrawn due to business decisions. No subjects were treated.","2012-05-04",{"date":57,"type":58},"2012-05-07","ESTIMATED",{"date":60,"type":25},"2010-09",{"date":62,"type":58},"2011-04",{"name":31,"class":6}]